SGLT2 抑制剂:从结构效应关系到药理反应
Teodora Mateoc1, Andrei-Luca Dumitrascu2, Corina Flangea3
1Doctoral School, Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
International journal of molecular sciences
|July 29, 2025
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂提供了超越2型糖尿病的广泛益处,改善心血管,和肝脏健康,以及肥胖. 它们的结构变化会影响疗效,影响脂质代谢和炎症.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 代谢疾病 代谢疾病
- 心血管和脏医学 心血管和脏医学
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂越来越多地用于2型糖尿病管理.
- 它们的治疗应用扩展到心血管,,肝脏疾病,以及代谢综合征中的肥胖症.
研究的目的:
- 审查SGLT2抑制剂在代谢综合征和相关疾病中的作用机制.
- 探索gliflozins的结构-活性关系及其对药理动力学和药理动力学特性的影响.
- 讨论开发新的治疗用途和减轻不良影响的潜力.
主要方法:
- 对SGLT2抑制剂的现有文献的审查,重点关注它们的化学结构和生物效应.
- 分析碳水化合物,甘氨酸和甘氨酸结合物的修改如何影响药物特性.
- 检查对葡萄糖代谢,脂质代谢和炎症通路的影响.
主要成果:
- SGLT2 抑制剂可以改善血糖控制,并通过促进脂质的调动和利用,对脂质代谢产生积极影响.
- 这些药物通过减少亲炎性介质和调节细胞信号来表现出抗炎性质.
- 结构-活性关系分析揭示了分子修饰如何与治疗结果相关.
结论:
- SGLT2 抑制剂对代谢综合征和相关疾病具有多方面的治疗益处.
- 了解gliflozin的结构效果关系可以指导新型治疗应用的开发.
- 需要进一步的研究来扩大适应症和解决不良影响,例如下肢截肢.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
01:27Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
01:24Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
01:15G Protein-coupled Receptors
13.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.5K
01:03Dose-Response Relationship: Overview
3.7K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.7K
01:29The Two-State Receptor Model
2.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.4K